Objective
to report the 5-year clinical outcome of Absorb bioresorbable vascular scaffold (BVS) compared with everolimus-eluting stent (Xience) for PCI of coronary lesions
Study
investigator-initiated, non-inferiority, randomised trial
Population
patients undergoing PCI of lesions suitable for BVS or Xience
Endpoints
target vessel failure vs cardiac death, target-vessel MI or target-vessel revascularisation at 5 years
Conclusion
at 5 years follow-up there is no statistically difference in the rate of adverse events between percutaneous treatment with BVS and Xience stents
Kerkmeijer et al. EuroIntervention. 2022; March
